Required section · Section 5 of 6
The shortage notice: what do you recommend
The manufacturer's supply-disruption notice caps troponin reagent shipments at 60 percent of this laboratory's historical order for the next two ordering cycles. On-hand inventory is 8 packs, 736 reportable tests. Monthly consumption is 1,528 tests. At the full run rate, 8 packs covers roughly 736 divided by 50.9 tests per day, about 14 to 15 days, before the shelf is empty, well inside the current reorder cycle.
The Food and Drug Administration (FDA) maintains a Medical Device Shortages List that publicly tracks device and in vitro diagnostic shortages by product code, and FDA does not prescribe a mandatory clinical-prioritization or allocation formula for laboratories facing a shortage; manufacturer allocation to distributors is one recognized supply-side mitigation measure, not a laboratory-level rule. There is no single authoritative, laboratory-specific ethical framework from CMS, CAP, or CLSI that ranks patients or test categories during a reagent shortage.
During the 2021 to 2022 US blood-collection-tube shortage, CDC and FDA guidance focused on conservation: do not collect a scarce tube unless the test is medically necessary, do not use it as a discard tube, and consolidate orders where clinically appropriate; CAP separately published strategies for that shortage, and the tube manufacturer warned that substitutes should not be chosen by cap color alone.
The scope boundary here is explicit: accounting conventions and purchasing authority are local, and financial or supply pressure never justifies noncompliance, unsafe staffing, or an unvalidated substitution. A troponin result supporting acute coronary syndrome rule-out is not a test to delay or withhold to conserve inventory.
With those constraints in view, decide what this laboratory should do in the next 24 hours, and be ready to state your assumptions.
A shortage response is a bounded, locally governed decision: confirm the shortage, protect essential and urgent testing, validate any substitute before it goes live, and communicate. It is not a fixed national algorithm or a reason to withhold a clinically indicated test.
Ordering exercise
Put this laboratory's response to the troponin shortage notice in a defensible sequence, from the first action taken to the last.
1. Evaluate a validated alternate
Check whether a validated alternate analyzer channel or send-out arrangement already exists; do not bring an unvalidated substitute into patient testing under time pressure.
2. Escalate and communicate
Notify the laboratory director and ordering clinicians of the constrained supply and the plan, so acute coronary syndrome rule-out testing is never delayed without clinicians knowing why.
3. Confirm the shortage
Check the manufacturer's notice against the FDA Medical Device Shortages List to confirm scope and expected duration before changing any workflow.
4. Reduce non-essential consumption
Consolidate or reduce non-essential repeat and duplicate orders that do not affect an active clinical decision, without touching medically necessary testing.
5. Quantify the runway
Calculate days of inventory remaining at current consumption: 8 packs on hand (736 tests) divided by about 50.9 tests per day, roughly 14 to 15 days.
Knowledge checks
Reading and checks are open. Sign in only to save.
Knowledge check 1
Knowledge check 2
Section status
Finish this section
Reading and checks are open. Sign in only to save.
The module finishes after every required section is marked done and every check in those sections is correct.